Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial

BACKGROUND: Limited data compare once-daily options for initial therapy for HIV-1. OBJECTIVE: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavir...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Daar, Eric S., Tierney, Camlin, Fischl, Margaret A., Sax, Paul E., Mollan, Katie, Budhathoki, Chakra, Godfrey, Catherine, Jahed, Nasreen C., Myers, Laurie, Katzenstein, David, Farajallah, Awny, Rooney, James F., Pappa, Keith A., Woodward, William C., Patterson, Kristine, Bolivar, Hector, Benson, Constance A., Collier, Ann C.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3430716/
https://ncbi.nlm.nih.gov/pubmed/21320923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1059/0003-4819-154-7-201104050-00316
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky